Proliferation markers and cell cycle inhibitors in pituitary adenomas

Frontiers of Hormone Research

Volumn 32, Issue , 2004, Pages 110-126

  Saeger, Wolfgang ^a  

^a Institute of Pathology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADENOMA; CELL CYCLE; CELL DIVISION; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; PATHOLOGY; REVIEW;

ADENOMA; CELL CYCLE; CELL DIVISION; HUMANS; PITUITARY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 4043097774     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000079040     Document Type: Article

References (72)

1. Krämer A, Saeger W, Tallen G, Lüdecke DK: DNA measurement, proliferation markers, and other factors in pituitary adenomas. Endocr Pathol 1994;5:198-211.
2. Lüdecke DK, Beck-Bornholt HP, Saeger W, Schmidt W: Tumour ploidy in DNA histograms of pituitary adenomas. Acta Neurochir (Wien) 1985;76:18-22.
3. Anniko M, Tribukait B, Wersäll J: DNA ploidy and cell phase in human pituitary tumors. Cancer 1984;53:1708-1713.
4. Kontogeorgos G, Kapranos N, Rologis D, Vamvassakis E, Papadopoulos N: DNA measurement in pituitary adenomas assessed on imprints by image analysis. Anal Quant Cytol Histol 1996; 18: 144-150.
5. Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB: Cyclin D and cyclin E expression in normal and adenomatous pituitary. Eur J Endocrinol 2000;143:R1-R6.
6. Yu R, Melmed S: Oncogene activation in pituitary tumors. Brain Pathol 2001;11:328-341.
7. Turner HE, Nagy Z, Sullivan N, Esiri MM, Wass JAH: Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clin Endocrinol 2000;53:337-344.
8. Saeger W, Schreiber S, Lüdecke DK: Cyclins Dl and D3 and topoisomerase Ha in inactive pituitary adenomas. Endocr Pathol 2001;12:39-47.
9. Nakabayashi H, Sunada I, Hara M: Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 2001;49:1193-1194.
10. Waseem NH, Lane DP: Monoclonal analysis of the proliferating cell nuclear antigen. Structural conversation and the detection of a nucleolar form. J Cell Sci 1990;96:121-129.
11. Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, Hedley WE: Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 1993;78:753-761.
12. Klencki M, Kurnatowska I, Slowinska-Klencka D, Lewinski A, Pawlikowski M: Correlation between PCNA expression and AgNOR dots in pituitary adenomas. Endocr Pathol 2001;12:163-169.
13. Schreiber S, Saeger W, Lüdecke DK: Proliferation markers in different types of clinically nonsecreting pituitary adenomas. Pituitary 1999; 1:213-220.
14. Nose-Alberti V, Mesquita MIS, Martin LC, Kayath MJ: Adrenocorticotropin-producing pituitary carcinoma with expression of c-erbB-2 and high PCNA index: A comparative study with pituitary adenomas and normal pituitary tissues. Endocr Pathol 1998;9:53-62.
15. Gandour-Edwards R, Kapadia SB, Janecka IP, Martinez AJ, Barnes L: Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Mod Pathol 1995;8:160-164.
16. Kawamoto H, Uozumi T, Arita K, Yano T, Hirohata T: Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 1995; 136:37-43.
17. Otsuka F, Tamiya T, Yamauchi T, Ogura T, Ohmoto T, Makino H: Quantitative analysis of growthrelated factors in human pituitary adenomas - Lowered insulin-like growth factor-I and its receptor mRNA in growth hormone-producing adenomas. Regul Peptides 1999;83:31-38.
18. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13.
19. Gerdes J, Becker MHG, Key G, Cattoretti G: Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 1992;168:85-86.
20. Solcia E, Klöppel G, Sobin LH, Capella C, de Lellis RA, Heitz PU, Horvath E, Kovacs K, Lack EE, Lloyd RJ, Rosai J, Scheithauer BW: Histological Typing of Endocrine Tumours. Berlin, Springer, 2000, pp 1-149.
21. Shibuya M, Saito F, Miwa T, Davis RL, Wilson CB, Hoshino T: Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase a monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol (Berlin) 1992;84:178-183.
22. Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Ruggeri A, Peciarolo A: Adrenocorticotropic hormone-secreting pituitary adenomas: Analysis of growth fraction using the MIB-1 antibody. Tumori 2000;86:229-232.
23. Kitz K, Knosp E, Koos WT, Korn A: Proliferation in piutuitary adenomas: Measurement by MAb Ki-67. Acta Neurochir (Wien) 1991;53:60-64.
24. Knosp E, Kitz K, Perneczky A: Proliferation activity in pituitary adenomas: Measurement by monoclonal antibody Ki-67. Neurosurgery 1989;25:927-930.
25. Landolt AM, Shibata T, Kleihues P: Growth rate of human pituitary adenomas. J Neurosurg 1987;67:803-806.
26. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr: Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-106.
27. Ekramullah SM, Saitoh Y, Arita N, Ohnishi T, Hayakawa T: The correlation of Ki-67 staining indices with tumor doubling times in regrowing non-functioning pituitary adenomas. Acta Neurochir (Wien) 1996;138:1449-1455.
28. Losa M, Franzin A, Mangili F, Terreni MR, Barzaghi R, Veglia F, Mortini P, Giovanelli M: Proliferation index of nonfunctioning pituitary adenomas: Correlations with clinical characteristics and long-term follow-up results. Neurosurgery 2000;47:1313-1318.
29. TanakaY, Hongo K, TadaT, Sakai K, KakizawaY, Kobayashi S: Growth pattern and rate in residual nonfunctioning pituitary adenomas: Correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 2003;98:359-365.
30. Calle-Rodrigue RDE, Giannini C, Scheithauer BW, Lloyd RY Wollan PC, Kovacs K, Stefaneanu L, Ebright AB, Abboud CF, Davis DH: Prolactinomas in male and female patients: A comparative clinicopathologic study. Mayo Clin Proc 1998;73:1046-1052.
31. Woloschak M, Yu AQ, Post KD: Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog 1991 ;19-.221-224.
32. Ruebel KH, Jin L, Zhang SY, Scheithauer BW, Lloyd RV: Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas. Endocr Pathol 2001; 12:281-289.
33. Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE: Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer 1999;24:328-336.
34. Lloyd RY Jin L, Qian X, Kulig E: Aberrant p27kipl expression in endocrine and other tumors. Am J Pathol 1997; 150:401-407.
35. Bamberger CM, Fehn M, Bamberger AM, Lüdecke DK, Beil FU, Saeger W, Schulte HM: Reduced expression levels of the cell-cycle inhibitor p27(Kipl) in human pituitary adenomas. Eur J Endocrinol 1999;140:250-255.
36. Komatsubara K, Tahara S, Umeoka K, Sanno N, Termaoto A, Osamura RY: Immunohistochemical analysis of p27 (Kipl) in human pituitary glands and in various types of pituitary adenomas. Endocr Pathol 2001;12:181-188.
37. Gaffey TA, Scheithauer BW, Lloyd RY Burger PC, Robbins P, Fereidooni F, Horvath E, Kovacs K, Kuroki T, Young WF, Sebo TJ, Riehle DL, Beizberg AJ: Corticotroph carcinoma of the pituitary: A clinicopathological study. J Neurosurg 2002;96:352-360.
38. Valtonen S, Myllimäki K: Outcome of patients after transcranial operation for pituitary adenoma. Ann Clin Res 1986;18(suppl 47):43-45.
39. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB: Expression of phosphorylated p27(Kipl) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002;87: 2635-2643.
40. Stefaneanu L, Kovacs K, Scheithauer BW, Kontogeorgos G, Riehle DL, Sebo TJ, Murray D, Vidai S, Tran A, Buchfelder M, Fahlbusch R: Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol 2000;11:341-352.
41. Liu W, Asa SL, Ezzat S: Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. Brain Pathol 2002;12:412-419.
42. Gannon JY Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-1602.
43. Sumi T, Stefaneanu L, Kovacs K, Asa SL, Rindi G: Immunohistochemical study of p53 protein in human and animal pituitary tumors. Endocr Pathol 1993;4:95-99.
44. Buckley N, Bates AS, Broome JC, Strange RC, Perrett CW, Burke CW, Clayton RN: p53 protein accumulates in Cushing's adenomas and invasive non-functional adenomas. J Clin Endocrinol Metab 1994;79:1513-1516.
45. Copelli SB, Coll MAL, Bruno OD: Absence of mutations in the p53 tumor suppressor gene in non-invasive Gushing adenomas. Medicina (B Aires) 1999;59:459-462.
46. Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa-Coutinho LM, Ferreira NP: Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res 2002;35:561-565.
47. Espay AJ, Azzarelli B, Williams LS, Bodensteiner JB: Recurrence in pituitary adenomas in child-hood and adolescence. J Child Neurol 2001;16:364-367.
48. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr: p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:765-770.
49. Roncaroli F, Scheithauer BW, Young WF, Horvath E, Kovacs K, Kros JM, Al Sarraj S, Lloyd RY Faustini-Fustini M: Silent corticotroph carcinoma of the adenohypophysis - A report of five cases. Am J Surg Pathol 2003;27:477-486.
50. Kumar K, Macaulay RJB, Kelly M, PirlotT: Absent p53 immunohistochemical staining in a pituitary carcinoma. Can J Neurol Sci 2001;28:174-178.
51. Saeger W, Lüdecke DK, Bergmann M, Schuppert F, Bosse U, Herbst H, Pagotto U: Pituitary carcinoma: Definition, incidence, characteristics and case reports. Pathol Res Pract 1999; 195:296, abstr 78.
52. Wellhausen L, Saeger W, Müller W, Derwahl M, Harnacher C, Lüdecke DK: Gs a, protein kinase C, cathepsin D, growth factors, estrogen receptor-related protein, and p53 in prolactin cell adenomas and null cell adenomas of the pituitary. Endocr Pathol 1998;9:135-148.
53. Müller W, Saeger W, Wellhausen L, Derwahl KM, Harnacher C, Lüdecke DK: Markers of function and proliferation in non-invasive and invasive bi- and plurihormonal adenomas of patients with acromegaly: An immunohistochemical study. Pathol Res Pract 1999;195:595-603.
54. Vidai S, Kovacs K, Horvath E, Rotondo F, Kuroki T, Lloyd RV, Scheithauer BW: Topoisomerase lia expression in pituitary adenomas and carcinomas: Relationship to tumor behavior. Mod Pathol 2002;15:1205-1212.
55. Knappe UJ, Hagel C, Lisboa BW, L̈decke B, Saeger W: Expression of urokinase, its receptor, and its inhibitor in human pituitary adenomas and anterior pituitary lobe. Zentralbl Neurochir 1999; (suppl I):43-44.
56. Knappe UJ, Hagel C, Lisboa BW, L̈decke DK, Saeger W: Urokinase-type plasminogen activator is overexpressed in pituitary adenomas. Exp Clin Endocrinol Diabetes 2000;108(suppl 1):S 5, abstr vDo016.
57. Wilczak W, Saeger W, Knappe UJ, Hagel C, L̈decke DK: Urokinase, urokinase receptor, urokinase inhibitor, tissue plasminogen activator, and matrix metalloproteinase in pituitary adenomas. Endocr Pathol 2001;12:253.
58. Wyllie AH, Kerr JFR, Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol 1980;68:251-306.
59. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Kosmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;384:334-336.
60. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JAH, Harris AL: Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: Relationship to tumour behaviour. Br J Cancer 2000;82: 1441-1445.
61. Kulig E, Jin L, Qian X, Horvath E, Kovacs K, Stefaneanu L, Scheithauer BW, Lloyd RV: Apoptosis in nontumorous and neoplastic human pituitaries - Expression of the Bcl-2 family of proteins. Am J Pathol 1999;154:767-774.
62. Drewett N, Jacobi JM, Willgoss DA, Lloyd HM: Apoptosis in the anterior pituitary gland of the rat: Studies with estrogen and bromocriptine. Neuroendocrinology 1993;57:89-95.
63. Gavrieli Y, Scherman Y, Ban-Seasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentations. J Cell Biol 1992;119:493-501.
64. Ansari B, Coates PJ, Greenstein BD, Hall PA: In situ end labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993;170:l-8.
65. Green VL, White MC, Hipkin LJ, Jeffreys RV, Foy PM, Atkin SL: Apoptosis and p53 suppressor gene protein expression in human anterior pituitary adenomas. Eur J Endocrinol 1997; 136:382-387.
66. Kontogeorgos G, Sambaziotis D, Piaditis G, Karameris A: Apoptosis in human pituitary adenomas: A morphologic and in situ end-labeling study. Mod Pathol 1997;10:921-926.
67. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F, Giovanelli M: Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab 2001;86:5194-5200.
68. Vidai S, Horvath E, Kovacs K, Scheithauer BW, Lloyd RV, Kontogeorgos G: Ultrastructural features of apoptosis in human pituitary adenomas. Ultrastruct Pathol 2001;25:85-92.
69. Frankfurt O, Robb JA, Sugarbaker EV, Villa L: Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis. Exp Cell Res 1996;226:387-397.
70. Oka H, Jin L, Kulig E, Scheithauer BW, Lloyd RV: Pituitary adenylate cyclase-activating polypeptide inhibits transforming growth factor-β [-induced apoptosis in a human pituitary adenoma cell line. Am J Pathol 1999;155:1893-1900.
71. Simard M, Zhang W, Hinton DR, Chen TC, Weiss MH, Su YZ, Gopalakrishna R, Law RE, Couldwell WT: Tamoxifen-induced growth arrest and apoptosis in pituitary tumor cells in vitro via a protein kinase C-independent pathway. Cancer Lett 2002;185:131-138.
72. Hamilton HB, Hinton DR, Law RE, Gopalakrishna R, Su YZ, Chen ZH, Weiss MH, Couldwell WT: Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: Potential therapeutic application. J Neurosurg 1996;85:329-334.